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Background:  There  is no  clear consensus  about  antithrombotic  treatment  in  atrial  ﬁbrillation  (AF)  patients
at low-intermediate  thromboembolic  risk. Transesophageal  echocardiography  (TEE)  is  useful  for  predic-
tion of  thromboembolic  events  in  AF.
Methods  and results:  Of 498  patients  with  nonvalvular  AF,  incidence  of  stroke,  cardiac  events,  and  mortality
was  investigated  in  280  patients  with  CHADS2 score  0 or 1  (mean  age  64  years,  mean  follow-up  6.4 ±  3.1
years).  Left  atrial abnormality  (low  left atrial  appendage  ﬂow,  spontaneous  echo  contrast,  or  thrombi),
complex  aortic  plaque  (mobile,  ulcerated,  pedunculate,  or thickness  ≥  4 mm),  or  both  were  deﬁned  as  TEE
risk.  The  incidences  of  ischemic  stroke,  cardiovascular  events,  and  death  were  higher  in patients  with
TEE risk  than  in  those  without  the  risk  (2.0%/year  vs. 0.5%/year,  p  <  0.05; 4.7%/year  vs. 1.9%/year,  p <  0.01;
and 4.7%/year  vs.  2.0%/year,  p  < 0.01, respectively).  This  was also  true for  patients  with  CHADS2 score  of
0 (1.7%/year  vs.  0.3%/year,  p <  0.05;  4.1%/year  vs.  1.6%/year,  p <  0.05;  and  3.9%/year  vs.  1.4%/year,  p  <  0.01;
respectively).  On  multivariate  analysis,  TEE  risk  predicted  ischemic  stroke,  cardiovascular  events,  and
mortality independently  of clinical  variables  or  CHADS2 score.
Conclusions:  TEE  could  be  useful  for further  stratiﬁcation  of  patients  with  nonvalvular  AF stratiﬁed  at  low-
intermediate  risk  (CHADS2 score  0 or 1) and could  indicate  who  should  receive  anticoagulation  treatment.
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Risk stratiﬁcation schemes and thromboembolism in patients
ith atrial ﬁbrillation (AF) vary widely and have only limited
redictive ability [1,2]. CHADS2 score (1 point given for each of
ongestive heart failure, hypertension, age ≥ 75, and diabetes mel-
itus, and 2 points for prior stroke/transient ischemic attack) is a risk
tratiﬁcation scheme that is widely used owing to its convenience
nd modest accuracy [3]. However, there is no clear consensus
bout the need for antithrombotic treatment in AF patients at
ow-intermediate risk. Transesophageal echocardiography (TEE) is
seful for thromboembolic risk stratiﬁcation in AF. Abnormality
f the left atrium (LA) and aortic atherosclerosis detected by TEE
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are risk factors for stroke and thromboembolism in AF patients
[4,5]. The present study aimed to determine whether these vari-
ables in combination with clinical variables would be useful for
prediction of cardiovascular events in nonvalvular AF patients at
low-intermediate risk.
Methods
Study population
The study included 608 patients with AF, who  underwent TEE
at our University Hospital and gave written informed consent to
participate in the follow-up study. The indication for TEE was
an evaluation of the potential thromboembolic risk. We  excluded
82 patients with mitral stenosis and mechanical valve replace-
ment. Also excluded were 28 patients because of inadequate TEE
images. Patients in the acute phase of cardiovascular diseases
or infection were excluded. Of the remaining 498 patients with
vier Ltd. All rights reserved.
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Table  1
Clinical characteristics of patients with CHADS2 score = 0 and 1.
CHADS2 score 0 and 1 (n = 280) 0 (n = 139) 1 (n = 141) p-Value*
Age (years) 64 ± 11 61 ± 11 67 ± 10 <0.001
Men 201 (73) 101 (73) 100 (73) 0.94
Chronic AF 135 (48) 54 (39) 81 (57) <0.01
Heart  failure 36 (13) 0 (0) 36 (26) <0.001
Hypertension 57 (20) 0 (0) 57 (40) <0.001
Age  ≥ 75 years 36 (13) 0 (0) 36 (26) <0.001
Diabetes mellitus 12 (4) 0 (0) 12 (9) <0.001
Antiplatelet drugs 50 (18) 25 (18) 25 (18) 0.96
Warfarin 196 (70) 92 (66) 104 (74) 0.17
PT-INRa 1.5 ± 0.8 1.4 ± 0.5 1.6 ± 0.9 0.34
LAD  (mm) 40  ± 8 39 ± 8 41 ± 8 0.09
LAD  ≥ 40 mm 135 (48) 50 (36) 85 (60) <0.001
LVEF  < 45% 31 (11) 13 (9) 18 (13) 0.36
TEE  risk 143 (51) 58 (42) 85 (60) <0.01
LAA  abnormality 80 (29) 34 (24) 46 (33) 0.15
Complex aortic plaque 97 (35) 38 (27) 59 (42) <0.05
Values are mean value ± SD or number (%) of patients.
AF, atrial ﬁbrillation; LAA, left atrial appendage; LAD, left atrial dimension; LVEF, left ventricular ejection fraction; PT-INR, prothrombin time-international normalized ratio
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a PT-INR was  determined only in patients on warfarin.
* For CHADS2 score = 0 vs. 1.
onvalvular AF (mean age 67 years, 363 men, mean follow-up
.7 ± 3.2 years), 280 patients with CHADS2 score 0 or 1 (mean age
4 years, 204 men) were recruited and long-term clinical outcomes
ere retrospectively determined (mean follow-up 6.4 ± 3.1 years).
aseline clinical characteristics including CHADS2 score risk factors
or each patient were obtained from medical records. The study
as approved by an institutional ethics committee, and informed
onsent was obtained from each patient.
chocardiography
TEE was performed with a 5-MHz multiplane transducer as
eported previously [6].  Brieﬂy, patients were studied in the fasting
tate with topical anesthesia of the pharynx. LA appendage ﬂow
elocity, LA spontaneous echo contrast, presence of LA thrombi,
nd aortic plaque were determined. LA abnormality was deﬁned
s thrombi in LA/LA appendage, dense spontaneous echo contrast,
r peak LA appendage ﬂow velocity ≤20 cm/s [4].  Complex aortic
laque was deﬁned as mobile, ulcerated, pedunculate, or thickness
4 mm [4,7].
utcomes
From the index date of TEE until October 2008, occurrence of
he composite endpoint of death from any cause, ischemic stroke,
nd cardiac events (myocardial infarction or admission for heart
ailure) was determined. Stroke was deﬁned as a sudden onset of
eurological deﬁcit lasting >24 h and was conﬁrmed by brain com-
uted tomography or magnetic resonance imaging if the patient
as admitted to Toyama University Hospital. Myocardial infarction
as deﬁned as typical chest symptoms with electrocardiographic
hanges and increases in cardiac enzymes. Stroke and cardiac
vents constituted cardiovascular events. Information on the end-
oints was collected from the medical records and questionnaires
nswered by patients themselves or their relatives.
tatistical analyses
Data are expressed as mean ± SD. All analyses were performed
sing SPSS (SPSS 11.0J, Chicago, IL, USA). The mean values and pro-
ortion of variables were compared with unpaired Student’s t test,
nalysis of variance for continuous variables, and 2 test for cate-
orical variables. The outcomes were displayed with Kaplan–Meierevent-free survival curves and compared with the log-rank test.
Cox proportional hazard regression was  used to compare the inde-
pendent effect of each factor. Variables used for the multivariable
models were: gender, age, TEE risk, warfarin usage, history of heart
failure, hypertension, and diabetes mellitus. A p-value <0.05 was
considered statistically signiﬁcant.
Results
Baseline characteristics
Table 1 shows clinical characteristics of patients with CHADS2
scores = 0 and 1. Patients with CHADS2 score = 1 were older, and had
higher frequency of chronic AF than those with CHADS2 score = 0.
The use of antiplatelet drugs and warfarin, and mean prothrombin
time-international normalized ratio were not signiﬁcantly differ-
ent between the groups. There were more patients with left atrial
dimension ≥ 40 mm and TEE risk for CHADS2 score = 1 than with
CHADS2 score = 0.
Outcomes
During the follow-up period, 58 of 280 (20.7%) patients died, 36
(12.9%) had cardiac events (4 myocardial infarction and 32 hospi-
talization for worsening of heart failure), 20 (7.1%) had ischemic
stroke, and 4 (1.4%) had bleeding events (2 with cerebral bleeding
and 2 with gastrointestinal bleeding). Incidences of ischemic stroke,
cardiovascular events, and mortality were signiﬁcantly higher in
patients with TEE risk than in those without it (2.0%/year vs.
0.5%/year, p < 0.05; 4.7%/year vs. 1.9%/year, p < 0.01; and 4.7%/year
vs. 2.0%/year, p < 0.01; respectively) (Fig. 1). These ﬁndings were
also true for patients with CHADS2 score 0 (Fig. 2).
Annual event rates and hazard ratios according to combina-
tions of TEE risk and CHADS2 score (0 or 1) are shown in Table 2.
Compared with patients with CHADS2 score = 0 and absence of TEE
risk, patients with CHADS2 score = 1 and TEE risk showed markedly
higher rates of ischemic stroke, cardiovascular events, and all-cause
mortality. Even among patients with CHADS2 score = 0, event risks
were 3–5 times higher when TEE risk was present. On multivariate
analysis, TEE risk predicted all-cause death, cardiovascular events,
and ischemic stroke independently of clinical variables (Table 3) or
CHADS2 score (Table 4). History of myocardial infarction was  not
an independent predictor for adverse outcomes.
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Table 2
Annual event rate and hazard ratio (95% conﬁdence intervals) for all-cause death,
cardiovascular events, and ischemic stroke according to combinations of TEE risk
and  CHADS2 score = 0 or 1.
Event
(%/year)
HR (95% CI) p-Value
All-cause death
CHADS2 score = 0, TEE risk− 1.4 1.00
CHADS2 score = 0, TEE risk+ 3.9 3.27 (1.36–7.86) <0.01
CHADS2 score = 1, TEE risk− 3.1 2.26 (0.92–5.53) 0.08
CHADS2 score = 1, TEE risk+ 5.3 4.05 (1.81–9.04) <0.001
Cardiovascular events
CHADS2 score = 0, TEE risk− 1.6 1.00
CHADS2 score = 0, TEE risk+ 4.1 2.68 (1.13–6.34) <0.05
CHADS2 score = 1, TEE risk− 2.4 1.54 (0.61–3.90) 0.36
CHADS2 score = 1, TEE risk+ 5.1 3.41 (1.55–7.51) <0.01
Ischemic stroke
CHADS2 score = 0, TEE risk− 0.3 1.00
CHADS2 score = 0, TEE risk+ 1.8 5.00 (1.00–24.97) <0.05
CHADS2 score = 1, TEE risk− 0.8 2.16 (0.36–12.93) 0.40
CHADS2 score = 1, TEE risk+ 2.1 6.57 (1.41–30.59) <0.05
Adjusted for sex.
HR, hazard ratio; CI, conﬁdence interval; TEE, transesophageal echocardiography.
Table 3
Cox proportional hazard analysis for predictors of clinical variables for all-cause
death and cardiovascular events among patients with CHADS2 score = 0 and 1.
Hazard ratio 95% CI p-Value
All-cause death
Male 1.74 0.86–3.52 0.12
Heart failure 2.28 0.98–5.29 0.05
Hypertension 1.26 0.57–2.81 0.56
Age  ≥ 75 years 3.76 1.83–7.73 <0.001
Diabetes mellitus 0.83 0.19–3.63 0.81
TEE  risk 3.28 1.76–6.11 <0.001
Warfarin 0.23 0.13–0.42 <0.001
Cardiovascular events
Male 1.02 0.55–1.90 0.94
Heart failure 1.38 0.59–3.25 0.46
Hypertension 1.37 0.67–2.79 0.39
Age  ≥ 75 years 1.98 0.87–4.54 0.11
Diabetes mellitus 0.52 0.07–3.97 0.53
TEE  risk 2.51 1.35–4.66 <0.01
Warfarin 0.84 0.43–1.63 0.61
Ischemic stroke
Male 1.49 0.53–4.18 0.45
Heart failure 0.38 0.05–3.15 0.37
Hypertension 1.52 0.49–4.66 0.47
Age  ≥ 75 years 3.61 1.15–11.27 <0.05
Diabetes mellitus 1.53 0.19–12.51 0.69
TEE  risk 4.10 1.43–11.75 <0.01
Warfarin 0.87 0.31–2.49 0.80
CI, conﬁdence interval; TEE, transesophageal echocardiography.
TEE risk includes left atrial abnormality, complex aortic plaque, or both.
Table 4
Cox proportional hazard analysis for predictors of all-cause death and cardiovascular
events among patients with CHADS2 score = 0 and 1.
Hazard ratio 95% CI p-Value
All-cause death
CHADS2 score = 1 1.93 1.09–3.44 <0.05
TEE risk 3.44 1.86–6.37 <0.001
Warfarin 0.24 0.13–0.42 <0.001
Cardiovascular events
CHADS2 score = 1 1.41 0.79–2.50 0.24
TEE  risk 2.59 1.40–4.79 <0.01
Warfarin 0.84 0.44–1.62 0.61
Ischemic stroke
CHADS2 score = 1 1.55 0.62–3.86 0.35
TEE  risk 4.00 1.40–11.39 <0.01
Warfarin 0.75 0.26–2.13 0.58
Adjusted for gender.
CI, conﬁdence interval; TEE, transesophageal echocardiography.
TEE risk includes left atrial abnormality, complex aortic plaque, or both.
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Fig. 1. Kaplan–Meier event-free survival curves for cardiovascular events (A) and
all-cause death (B) according to risk by transesophageal echocardiography (TEE)
among patients with CHADS2 score = 0 or 1.
Discussion
Major ﬁndings of the present study were as follows. First, in
AF patients with CHADS2 score = 0 or 1, TEE risk independently
of clinical variables or CHADS2 score predicted all-cause death,
cardiovascular events, and ischemic stroke. Second, combining
TEE risk with CHADS2 score improved risk evaluation for adverse
events. Long-term event risks were 3–5 times higher in patients
with TEE risk and CHADS2 score of 1 than in those without these
features. Third, patients with TEE risk had signiﬁcantly higher
event rates than those without TEE risk even among patients with
CHADS2 score of 0.
Current risk stratiﬁcation schemes for thromboembolism in
AF have only limited predictive ability and additional progno-
stic variables have been sought. LA abnormality and severe aortic
atherosclerosis detected by TEE are well-known risk factors for
thromboembolism in patients with nonvalvular AF [4].  LA spon-
taneous echo contrast and reduced LA appendage ﬂow velocity
are associated with LA thrombus formation [8–10], thromboem-
bolic events [4,10,11], or death [12]. LA spontaneous echo contrast
also relates to extensive atherosclerotic vascular disease as well
as cardioembolic high risk [12]. Aortic atherosclerosis is repre-
sentative of systemic atherosclerosis and a potential source of
arterial embolism. The relationship between aortic atherosclero-
sis detected by TEE and subsequent cardiovascular events has been
shown in patients at high risk for cardiovascular diseases [4,13,14],
but not in those at low-intermediate risk. CHADS2 score, a risk
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oig. 2. Kaplan–Meier event-free survival curves for cardiovascular events (A) all-
ause death (B) according to risk by transesophageal echocardiography (TEE) among
atients with CHADS2 score = 0.
tratiﬁcation scheme for thromboembolism in patients with non-
alvular AF, could predict mortality as well [15,16].  Both impaired
A function [17–19] and aortic atherosclerosis [17] are associated
ith higher CHADS2 score in AF patients. Recently, CHA2DS2-VASc
core [20] has been proposed for further thromboembolic (and
ortality) risk stratiﬁcation among patients with AF and a CHADS2
core of 0 or 1 [21].
Concerning pathogenic factors in TEE risk and higher CHADS2
core in patients with AF, inﬂammation, oxidative stress, and other
actors as well as traditional risk factors for atherosclerosis may
e related to poor outcomes. Hypercoagulability was reported in
F patients with LA abnormality [22,23] and large (≥4 mm)  aortic
laque [13]. Higher CHADS2 score also related to prothrombotic
tate in patients with AF [24]. Levels of hemostatic markers were
levated in nonvalvular AF patients with at least one risk factor
or embolism [25], severe aortic atherosclerosis [26], and aortic
pontaneous echocardiographic contrast [6].  In the APRIS (Aortic
laque and Risk of Ischemic Stroke) study, large aortic plaques were
ssociated with hypercoagulability in patients with acute ischemic
troke, and coexistence of large aortic plaques and hypercoagu-
ability was a risk factor for recurrent stroke and death [13]. A
ecent study showed that CHADS2 score was signiﬁcantly higher in
atients with LA appendage thrombi and that clinical variables in
ombination with TEE variables very well predicted cardioembolic
isk [8].  TEE ﬁndings directly demonstrate possible cardioembolic
ource or severity of atherosclerosis irrespective of the duration
r control status of coexisting diseases (e.g. heart failure, diabetesiology 60 (2012) 484–488 487
mellitus) or clinical characteristics of patients, and this might
explain the improvement in the risk prediction by combining TEE
ﬁndings with CHADS2 score in the present study.
In a study of patients before pulmonary vein isolation, the preva-
lences of LA thrombus/sludge were 0% and 2% in patients with
CHADS2 scores 0 and 1, respectively [19]. In the present study,
the prevalences of LA abnormality in patients with CHADS2 scores
0 and 1 were 24% and 33%, and those of complex aortic plaque
were 27% and 42%, respectively. Patients were older (67 vs. 57
years), and there were more patients with diabetes mellitus (16%
vs. 9%), heart failure (22% vs. 13%), history of coronary artery dis-
ease (18% vs. 16%), or CHADS2 score ≥ 2 (44% vs. 20%) in the present
study than in the previous study of patients undergoing catheter
ablation [19]. Therefore, there might be a certain proportion of
patients at high risk for cardiovascular or thromboembolic events,
even among those at low-intermediate risk stratiﬁed according to
current risk stratiﬁcation schemes. TEE is a semi-invasive proce-
dure, but this ﬁnding could give us useful information to determine
thromboembolic risk even at low-intermediate risk by clinical
backgrounds.
The present study had several limitations. First, the small sam-
ple size may  have affected statistical signiﬁcance. In addition, the
relationship between stroke subtypes and TEE ﬁndings could not be
detected. Second, neither medical therapy prior to events nor the
treatment status of antithrombotic drugs were determined during
the follow-up period in the present study. Warfarin usage was rela-
tively high in the present study. This high rate of warfarin use even
in low-risk patients is comparable to recent reports from Japan on
the phenomenon of overuse of warfarin [27,28]. However, the mean
prothrombin-international normalized ratio levels were below the
recommended level of Japanese guidelines [29,30]. In addition,
usage of antiplatelet drugs did not differ between the subgroups.
Therefore, antithrombotic treatments might not have affected the
present result. Third, subjects were selected from patients with
nonvalvular AF who  had TEE for evaluation of cardioembolic risk.
Therefore, patients seemed at relatively high risk for thromboem-
bolism, although their CHADS2 score was 0 or 1. There were some
patients without TEE risk but with CHADS2 score of 1 in the present
study. The information of CHADS2 score on end points was neither
considered. The number of patients with cardiac dysfunction but
without risk factors for atherosclerosis or clinical symptoms could
be underestimated according to the CHADS2 score.
Although limited for these reasons, the present study indicates
that combining TEE ﬁndings with CHADS2 score improved pro-
gnostic accuracy for ischemic stroke, cardiovascular events, and
mortality. Further studies are required to search for risk stratiﬁ-
cation factors among those with CHADS2 score of 0 or 1 using a
more sophisticated scheme such as CHA2DS2-VASc score.
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